Report Materials
EXECUTIVE SUMMARY:
This final report summarizes the results of our review of the Health Care Financing Administration's (HCFA) proposal to change the methodology for reimbursing separately billable drugs under Medicare's end stage renal disease (ESRD) program. Our results indicated that dialysis facilities purchase separately billable drugs significantly below the average wholesale price.
Notice
This report may be subject to section 5274 of the National Defense Authorization Act Fiscal Year 2023, 117 Pub. L. 263.